“If successful, [the drug] has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization.” The company described the drug as an “investigational orally administered protease inhibitor antiviral therapy designed specifically to combat COVID–19 – in non–hospitalized, symptomatic adult participants who have a confirmed diagnosis of SARS–CoV–2 infection
Taken directly from the article
46 posted on 09/01/2021 7:59:22 PM PDT by gas_dr
(Conditions of Socratic debate: Intelligence, Candor, and Good Will. )